Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, November 25, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Imperial Innovations Leads £50 Million Series B Funding Round in Cell Medica
Tuesday, November 25, 2014
Cell Medica will use the investment capital to progress further the development of cellular immunotherapy products.

Merck Millipore Launches Kit for Analyzing NF?B Translocation
Thursday, November 20, 2014
Permits quantitative, statistically robust assessment of NF?B translocation.

Agilent Introduces New Column Innovations for Biotherapeutics Development
Thursday, November 13, 2014
Reversed-phase columns optimized to separate monoclonal antibodies.

Merck Millipore's New SNAP i.d.® 2.0 System for Immunohistochemistry
Friday, November 07, 2014
Offers parallel processing of up to 24 slides at once, without the cost of automation.

Merck Millipore's Guava easyCyte™ 12 Flow Cytometer
Friday, November 07, 2014
Increased performance provides better sensitivity and resolution.

Innova Introduces Lightning-Link Rapid Bioconjugation Kits
Tuesday, November 04, 2014
New kits enable customers to conjugate primary antibodies in 20 minutes.

Improved Method for Protein Quality Control
Friday, October 31, 2014
Separation of intact monoclonal antibody sialylation isoforms by pH gradient ion-exchange chromatography.

Randox Launches World’s Most Comprehensive Third Party Haematology Control
Wednesday, October 29, 2014
Randox Laboratories has launched a third party multi-analyte haematology control; the most comprehensive haematology quality control (QC) solution on the market to date.

Bulldog Bio Provides Novel Adjuvant Enhancer for Improved Vaccinations
Tuesday, October 28, 2014
New Opticcine Adjuvant Enhancer improves immune response against a wide variety of antigens.

<< 1 2 3 4 5 6 7 >>
Showing Results 1 - 10 of 368
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv